Roxadustat for the treatment of anemia in patients with <scp>lower‐risk</scp> myelodysplastic syndrome: Open‐label, dose‐selection, lead‐in stage of a phase 3 studyDavid H. Henry, Kin-Hung P. Yu, Robert Leong et al.|American Journal of Hematology|2021Cited by 58
Exploring Spatial-Temporal Changes in <sup>18</sup>F-Sodium Fluoride PET/CT and Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer Treated With EnzalutamideChristos E. Kyriakopoulos, Glenn Liu, Elisabeth I. Heath et al.|Journal of Clinical Oncology|2020Cited by 29
Roxadustat versus placebo for patients with lower‐risk myelodysplastic syndrome: MATTERHORN phase 3, double‐blind, randomized controlled trialMoshe Mittelman, Katharina Modelska, David H. Henry et al.|American Journal of Hematology|2024Cited by 17
Efficacy and Safety of Roxadustat for Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndrome (LR-MDS) with Low Red Blood Cell (RBC) Transfusion Burden: Results of Phase III Matterhorn StudyMoshe Mittelman, Katharina Modelska, David H. Henry et al.|Blood|2023Cited by 5
Spatial-temporal change in quantitative total bone imaging (QTBI) and circulating tumour cells (CTCs) in metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA)G. Liu, Robert Jeraj, Christos E. Kyriakopoulos et al.|Annals of Oncology|2019Cited by 0